Results 81 to 90 of about 13,346 (214)
GD2 CAR T cells against human glioblastoma [PDF]
, 2021 Glioblastoma is the most malignant primary brain tumor and is still in need of effective medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 antigen expression representing a potential target for CAR T strategy.
Neri, Giovanni +56 more
core +1 more source
Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis
Advanced Science, EarlyView.This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun +15 more
wiley +1 more source
Two‐Dimensional Triferroics: From Fundamental Couplings to Multifunctional Applications
Advanced Science, EarlyView.This graphic summarizes the three main types of currently reported 2D triferroic couplings. From the structural perspective, existing systems can be broadly classified into two categories, which exhibit distinct symmetry features and coupling behaviors. Beyond the lattice difference, a third type involves the interplay among ferroelectricity, magnetism,
Yang Li, Jialin Gong, Zhiqing Li
wiley +1 more source
, 2022 Das Neuroblastom ist der häufigste, solide, extrakranielle Tumor im Kindesalter. Trotz umfassender Forschung beträgt die Überlebensrate im Hochrisikostadium nur ca. 50%.
Paasburg, Nadia
core
Advanced Science, EarlyView.ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply
, 2023 To the Editor: Del Bufalo et al. (April 6 issue)(1) describe the treatment of patients with relapsed or refractory pediatric neuroblastoma with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 and express the ...
Locatelli F.
core +1 more source
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
, 2023 Background: Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. Methods: In an academic, phase 1-2
M. Guercio +34 more
core +2 more sources
Advances in Cancer Immunotherapy for Solid Tumors
Advanced Science, EarlyView.Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz +1 more
wiley +1 more source
Advanced Energy Materials, EarlyView.A Gd‐doped Cu2O electrocatalyst disrupts rigid interfacial hydrogen‐bonding networks, creating a free‐water‐rich microenvironment. This accelerates proton‐coupled electron transfer, enabling selective high‐rate CO2‐to‐ethanol conversion with 48.5% Faradaic efficiency at industrially relevant current densities.
Hyunwoo Kim +11 more
wiley +1 more source
Advanced ScienceDisialoganglioside‐GD2 is a key molecular target for Neuroblastoma (NB) immunotherapy based on the employment of GD2‐targeting antibodies. However, about 50% of treated patients can experience tumor relapse due to limited immune‐mediated cytotoxicity and
Suleman Khan Zadran +25 more
doaj +1 more source